Terms: = Ovarian cancer AND ER, estrogen receptor
2289 results:
1. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or ovarian cancer.
Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
[TBL] [Abstract] [Full Text] [Related]
3. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
4. High incidence of imperforate vagina in ADGRA3-deficient mice.
Kvam JM; Nybo ML; Torz L; Sustarsic RK; Jensen KHR; Nielsen JE; Frederiksen H; Gadgaard S; Spiess K; Poulsen SS; Thomsen JS; Cowin P; Blomberg Jensen M; Kurita T; Rosenkilde MM
BMC Biol; 2024 Apr; 22(1):77. PubMed ID: 38589878
[TBL] [Abstract] [Full Text] [Related]
5. Stearoyl-CoA desaturase 1 inhibition induces ER stress-mediated apoptosis in ovarian cancer cells.
Lee J; Jang S; Im J; Han Y; Kim S; Jo H; Wang W; Cho U; Kim SI; Seol A; Kim B; Song YS
J Ovarian Res; 2024 Apr; 17(1):73. PubMed ID: 38566208
[TBL] [Abstract] [Full Text] [Related]
6. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response.
Hu Z; Wu Z; Liu W; Ning Y; Liu J; Ding W; Fan J; Cai S; Li Q; Li W; Yang X; Dou Y; Wang W; Peng W; Lu F; Zhuang X; Qin T; Kang X; Feng C; Xu Z; Lv Q; Wang Q; Wang C; Wang X; Wang Z; Wang J; Jiang J; Wang B; Mills GB; Ma D; Gao Q; Li K; Chen G; Chen X; Sun C
Nat Genet; 2024 Apr; 56(4):637-651. PubMed ID: 38565644
[TBL] [Abstract] [Full Text] [Related]
7. [Non-primary solid malignancies of breast in needle core biopsy: a clinicopathological analysis of 23 cases].
Gu WQ; Wang L; Xu JC; Ping GQ; Han X; Wang C
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):331-336. PubMed ID: 38556815
[No Abstract] [Full Text] [Related]
8. Is There a Special Role for ovarian Hormones in the Pathogenesis of Lobular Carcinoma?
Flaherty RL; Sflomos G; Brisken C
Endocrinology; 2024 Mar; 165(5):. PubMed ID: 38551031
[TBL] [Abstract] [Full Text] [Related]
9. A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.
Ottenbourgs T; van Gorp T; Kridelka F; Baert T; Denys H; Selle F; Baas I; Van Rompuy AS; Lambrechts D; Van Nieuwenhuysen E
Int J Gynecol Cancer; 2024 Apr; 34(4):627-630. PubMed ID: 38453176
[TBL] [Abstract] [Full Text] [Related]
10. Mesonephric-like adenocarcinoma of the ovary.
Yang Y; Zhao M; Jia Q; Tang H; Xing T; Li Y; Tang B; Xu L; Wei W; Zheng H; Shi R; Xia B; Chen J
J Ovarian Res; 2024 Mar; 17(1):57. PubMed ID: 38444000
[TBL] [Abstract] [Full Text] [Related]
11. A novel CSN5/CRT O-GlcNAc/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer.
Yan T; Ma X; Zhou K; Cao J; Tian Y; Zheng H; Tong Y; Xie S; Wang Y; Guo L; Lu R
Int J Biol Sci; 2024; 20(4):1279-1296. PubMed ID: 38385070
[No Abstract] [Full Text] [Related]
12. Unfolded Protein-Based Sandwich AIE Probe Imparts High Fluorescent Contrast for Pan-cancer Surgical Navigation.
Wang Q; Chen B; Duan C; Wang T; Lou X; Dai J; Xia F
Anal Chem; 2024 Feb; 96(8):3609-3617. PubMed ID: 38364862
[TBL] [Abstract] [Full Text] [Related]
13. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma.
Yadav A; Sistla A; Swain M; Gowrishankar S; Padua M; Modi T; Himabindu R; Agarwal N; Kulkarni A; Bhandari T; Vudayaraju H; Chinnababu ; Reddy VA
Indian J Pathol Microbiol; 2024; 67(1):62-67. PubMed ID: 38358190
[TBL] [Abstract] [Full Text] [Related]
14. Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
Ruiz F; Tjendra Y; Millan N; Gomez-Fernandez C; Pinto A
Am J Surg Pathol; 2024 May; 48(5):546-550. PubMed ID: 38357982
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
16. AURKA Enhances the Glycolysis and Development of ovarian Endometriosis Through ERβ.
Sun Y; Zhang S; Zhang X; Li G; Sun F; Wang M; Ren C; Jiang A; Yang T
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38340326
[TBL] [Abstract] [Full Text] [Related]
17. Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
Tang T; Yu H; Xu S; Zhong Y; Ma J; Zhao T
Int J Cancer; 2024 Jun; 154(11):1948-1954. PubMed ID: 38323658
[TBL] [Abstract] [Full Text] [Related]
18. The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Lin J; Liu L; Wang L; Ma N; Zhang K; Xie N; Yu H; Deng S; Sun Y
World J Surg Oncol; 2024 Feb; 22(1):42. PubMed ID: 38310233
[TBL] [Abstract] [Full Text] [Related]
19. Benzo[a]pyrene exposure affects colorectal cancer susceptibility by regulating ERβ-mediated LINC02977 transcription.
Ben S; Li S; Gu D; Zhao L; Xu S; Ding Z; Chen S; Cheng Y; Xin J; Du M; Wang M
Environ Int; 2024 Feb; 184():108443. PubMed ID: 38277997
[TBL] [Abstract] [Full Text] [Related]
20. Upgrade Rates and Breast cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions.
Laws A; Leonard S; Hershey E; Stokes S; Vincuilla J; Sharma E; Milliron K; Garber JE; Merajver SD; King TA; Pilewskie ML
Ann Surg Oncol; 2024 May; 31(5):3120-3127. PubMed ID: 38261128
[TBL] [Abstract] [Full Text] [Related]
[Next]
